A group of stakeholders called for FDA to provide greater clarity on its policies for incorporating patient engagement into the drug review process. At this point, the pharmaceutical industry is hesitant to implement patient engagement strategies due to ambiguity surrounding the regulatory framework, they said. The press for clarity from FDA comes as patient groups, researchers and drug manufacturers seek a streamlined approach for incorporating the patient voice in the drug development process. Stakeholders are calling for development of a...